Unpacking Key Data from ASH 2024 - Episode 1
Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024
Panelists discuss how key data from ASH 2024 impact current approaches to treating hematologic malignancies, with a focus on multiple myeloma, lymphoma, and leukemia.
Video content above is prompted by the following:
ASH 2024 Oncology Highlights for Physicians: Multiple Myeloma CAR T-Cell Therapy
Summary of Peer Exchange Discussion
An OncLive Peer Exchange focused on key data presented at the American Society of Hematology (ASH) 2024 Annual Meeting. The panel features experts:
- Andre Goy, MD
- Jamie Koprivnikar, MD
- Harsh Parmar, MD
The discussion aims to highlight significant abstracts and foster expert dialogue on recent developments in hematologic malignancies, specifically focusing on lymphoma, leukemia, and multiple myeloma.
The first abstract (#2408) under discussion examines real-world data comparing ciltacabtagene autoleucel (cilta-cel) vs idecabtagene vicleucel (ide-cel) in patients with relapsed multiple myeloma. Dr Parmar is invited to provide insights on how this real-world evidence might inform clinical decision-making for patients with multiple myeloma and potentially influence treatment selection between these 2 chimeric antigen receptor (CAR) T-cell therapies.
The discussion emphasizes the value of real-world data in understanding how approved therapies perform in clinical practice outside the controlled environment of clinical trials.
